Corporate News

Initiated Phase 1/ 2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory acute myeloid leukemia or myelodysplastic syndrome in the U.S.
Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor according to License Agreement with Ono Pharmaceutical
Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.
Published 5th financial report
Chordia Therapeutics Director and Statutory Auditor Appointments
Chordia named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022
Chordia’s licensee Ono Pharmaceutical Co., Ltd. initiated Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd
Concludes Basic Agreement on Business Tie up with MEDIPAL HOLDINGS CORPORATION
Raises Approximately 4 billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 billion JPY
Featured as a cover story in Startup City Magazine’s “Top 10 Japanese Startups 2022”
Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022
Published 4th financial report
Assignment of Statutory Auditor
Published in Scrip
Published in Answernews
Notice of license agreement
Chordia Therapeutics announced the appointment of CMO & CSO
Chordia Therapeutics Raises $~27 million in Series B Financing
Published our article in Forbes JAPAN
Presentation at the AMED seminar, BioJapan 2018
Chordia Therapeutics Raises $~11 million in Series A Financing
Launch of Chordia Therapeutics

Electronic Financial Report